Sotagliflozin, the first dual SGLT inhibitor: current outlook and perspectives

Cardiovascular Diabetology
Chiara Maria Assunta CefaloAndrea Giaccari

Abstract

Sotagliflozin is a dual sodium-glucose co-transporter-2 and 1 (SGLT2/1) inhibitor for the treatment of both type 1 (T1D) and type 2 diabetes (T2D). Sotagliflozin inhibits renal sodium-glucose co-transporter 2 (determining significant excretion of glucose in the urine, in the same way as other, already available SGLT-2 selective inhibitors) and intestinal SGLT-1, delaying glucose absorption and therefore reducing post prandial glucose. Well-designed clinical trials, have shown that sotagliflozin (as monotherapy or add-on therapy to other anti-hyperglycemic agents) improves glycated hemoglobin in adults with T2D, with beneficial effects on bodyweight and blood pressure. Similar results have been obtained in adults with T1D treated with either continuous subcutaneous insulin infusion or multiple daily insulin injections, even after insulin optimization. A still ongoing phase 3 study is currently evaluating the effect of sotagliflozin on cardiovascular outcomes (ClinicalTrials.gov NCT03315143). In this review we illustrate the advantages and disadvantages of dual SGLT 2/1 inhibition, in order to better characterize and investigate its mechanisms of action and potentialities.

References

Jul 1, 1976·The Journal of Clinical Investigation·R A DeFronzoZ S Agus
Apr 7, 2000·Diabetes/metabolism Research and Reviews·A Ceriello
Jun 18, 2003·Endocrinology·Younes Anini, Patricia L Brubaker
Jan 22, 2004·Biochemical and Biophysical Research Communications·Katrin ElfeberHermann Koepsell
Sep 29, 2004·JPEN. Journal of Parenteral and Enteral Nutrition·Andrea ScheepersAnnette Schürmann
Dec 28, 2004·Nature Medicine·Akira HirasawaGozoh Tsujimoto
Dec 30, 2004·Diabetes/metabolism Research and Reviews·Joel R L EhrenkranzJesse Roth
Mar 27, 2007·Diabetic Medicine : a Journal of the British Diabetic Association·R E Wachters-HagedoornR J Vonk
Jun 6, 2008·Diabetologia·C J BaileyJ H B Scarpello
Jun 10, 2008·Diabetes Care·David M NathanUNKNOWN A1c-Derived Average Glucose Study Group
Sep 18, 2008·American Journal of Physiology. Endocrinology and Metabolism·June ZhouMichael J Keenan
Dec 31, 2008·Diabetes Care·James F ListFred T Fiedorek
May 6, 2009·Annals of Internal Medicine·Andrew S LeveyUNKNOWN CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration)
Jan 20, 2010·European Journal of Heart Failure·Dirk von LewinskiBurkert Pieske
May 29, 2010·Nature Reviews. Drug Discovery·Edward C Chao, Robert R Henry
Apr 30, 2011·Physiological Reviews·Ernest M WrightBruce A Hirayama
Sep 20, 2011·Diabetic Medicine : a Journal of the British Diabetic Association·S L EllisS K Garg
Nov 15, 2012·American Journal of Physiology. Endocrinology and Metabolism·David R PowellBrian Zambrowicz
Mar 5, 2013·Expert Opinion on Investigational Drugs·William N Washburn, Simon M Poucher
Jul 26, 2013·The New England Journal of Medicine·Philip E Cryer
Nov 13, 2013·Diabetes·Teresa MezzaRohit N Kulkarni
Jan 28, 2014·The Journal of Clinical Investigation·Ele FerranniniHans-Juergen Woerle
Jun 29, 2014·Physiological Reports·Chiara GhezziErnest M Wright
Jul 6, 2014·PloS One·Antonella NapolitanoDerek J Nunez
Oct 12, 2014·Pflügers Archiv : European journal of physiology·Ivana VrhovacHermann Koepsell

❮ Previous
Next ❯

Citations

Aug 14, 2019·Expert Opinion on Investigational Drugs·Ernest AdeghateErnest A Adeghate
Mar 8, 2020·Pflügers Archiv : European journal of physiology·Volker Vallon
Apr 1, 2020·Journal of Clinical Medicine·Angelo Maria PattiFerdinando Mannello
Mar 21, 2020·Journal of Diabetes Investigation·Ryuhei SanoTakeshi Ohta
Jun 24, 2020·International Journal of Immunopathology and Pharmacology·Chieh-Shan WuChi-Chien Lin
Sep 16, 2019·Current Cardiology Reports·Cezary Wojcik, Bruce A Warden
Jan 7, 2020·European Heart Journal·John G F ClelandJohn J V McMurray
Mar 11, 2020·Nature Reviews. Nephrology·Volker Vallon, Scott C Thomson
Jun 28, 2020·Cardiovascular Diabetology·Lihua NiXiaoyan Wu
Sep 5, 2020·Drug Design, Development and Therapy·Xolani H MakhobaOfentse J Pooe
Dec 10, 2020·Cardiac Failure Review·Giuseppe RosanoFelipe Martínez
Jan 9, 2021·Cardiovascular Diabetology·David BodeFelix Hohendanner
Feb 3, 2021·Current Opinion in Biotechnology·Lin PanGuangli Yu
Mar 9, 2021·Endocrinology and Metabolism·Eun-Jung RheeWon-Young Lee
Jul 28, 2020·Biochimica Et Biophysica Acta. Molecular Basis of Disease·Yoshifumi SatoKazuya Yamagata
Mar 31, 2021·Journal of Medicinal Chemistry·Andrew C FlickChristopher J O'Donnell
Mar 31, 2021·Metabolism Open·Natalia G VallianouMaria Dalamaga
May 14, 2021·European Journal of Pharmacology·Prabhsimran KaurAnjana Munshi
May 18, 2021·World Journal of Diabetes·Tess Montada-Atin, G V Ramesh Prasad
Jul 26, 2021·European Journal of Pharmacology·João FariaRosalinde Masereeuw
Aug 2, 2021·Metabolism: Clinical and Experimental·Jae-Seung Yun, Seung-Hyun Ko

❮ Previous
Next ❯

Clinical Trials Mentioned

NCT01986881
NCT03315143
NCT03313752
NCT01441232
NCT03351478
NCT02384941
NCT02421510

Software Mentioned

CANVAS
EMPAREG

Related Concepts

Related Feeds

Autoimmune Diabetes & Tolerance

Patients with type I diabetes lack insulin-producing beta cells due to the loss of immunological tolerance and autoimmune disease. Discover the latest research on targeting tolerance to prevent diabetes.

© 2022 Meta ULC. All rights reserved